SLRN קפיטליזציה חשבונאית ACELYRIN

The market trend for Acelyrin, Inc. (SLRN) shares is fixed at 0.40. The company's supply stability is ensured by strict temperature control during the transportation of biologics to medical centers. The business relies on the creation of small proteins for the therapy of skin pathologies that overcome tissue barriers. However, a lack of sales and challenges with clinical trials have led to a partial investor exodus, and development is currently focused on patents under FDA supervision.

Book value reflects the total value of net assets, determining the fundamental stability of the business through the difference between all assets and liabilities. Analysis of the book equity chart allows for tracking the real growth of resources at Acelyrin, Inc. (SLRN), which is critical for assessing the investment efficiency in developing high-margin drugs for the treatment of autoimmune diseases.